Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009
Side effects of chemical preparations in patients with drug-resistant pulmonary tuberculosis Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015
Evaluating the use of the interferon-γ response to mycobacterium tuberculosis (MTB) specific antigens to diagnose latent tuberculosis infection in patients with chronic inflammatory joint and skin diseases Source: Annual Congress 2011 - Tuberculin skin tests, interferon-gamma release assays and beyond Year: 2011
Clinical relevance of Mycobacterium simiae in pulmonary samples Source: Eur Respir J 2008; 31: 106-109 Year: 2008
Diagnosis and treatment‘s management of the MDR tuberculosis in a chronic pulmonary diseases department Source: Eur Respir J 2005; 26: Suppl. 49, 651s Year: 2005
Resistant tuberculosis and accompanying diseases Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002
Economic aspects of enhanced testing strategies for respiratory diseases Source: Value-Dx event 2021: Community-acquired respiratory tract infections: where do we stand in 2021, ECCMID 2021 Year: 2021
Phytotherapy in complex treatment of destructive tuberculosis of the lungs Source: Eur Respir J 2005; 26: Suppl. 49, 646s Year: 2005
Prevalence and low diagnostics of chronic non-specific pulmonary diseases among pulmonary TB patients Source: Annual Congress 2007 - Tuberculosis control in the penitentiary and civilian sector Year: 2007
Accidental detection of mycobacterium tuberculosis infection in patients with various respiratory diseases Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008
Diagnosis of respiratory diseases in the patients with tuberculosis of the spine Source: Eur Respir J 2006; 28: Suppl. 50, 20s Year: 2006
When is an infectious disease? The clinical spectrum of nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019
Rare lung diseases in children: challenges for diagnosis and treatment Source: Virtual Congress 2021 – Rare lung diseases 2021 Year: 2021
Current problems of acute destructive infection diseases of the lungs in children Source: Eur Respir J 2004; 24: Suppl. 48, 627s Year: 2004
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Source: Eur Respir J 2010; 35: 606-613 Year: 2010
The cases of active tuberculosis among persons with latent tuberculosis infection residing in the disease hot spots Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Impact of bacterial infections on airway diseases Source: Eur Respir Rev 2005; 14: 62-68 Year: 2005
Associated diseases and chronic tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 154s Year: 2003
Treatment of nontuberculous mycobacterial pulmonary diseases (slow-growing organisms): an interactive session Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019
Impact of underlying respiratory diseases on clinical features and prognosis of chronic pulmonary aspergillosis Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015